Causal effect of serum matrix metalloproteinase levels on venous thromboembolism: a Mendelian randomization study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
OBJECTIVES Serum matrix metalloproteinase (MMP) levels are associated with cardiovascular diseases. However, the causal associations between serum levels of specific MMPs and venous thromboembolism (VTE) remain unclear. The present study sought to explore the causal relationship between serum MMP levels and VTE by using the Mendelian randomization (MR) method. METHODS In this study 2-sample MR study, the exposure data on serum MMP levels were derived from genome-wide association studies involving 21,758 individuals from 13 cohorts of European descent. The outcome data on VTE, including deep vein thrombosis and pulmonary embolism, were derived from the FinnGen research project. The primary method used was the inverse-variance weighting method. The MR-Egger intercept test and the Cochran Q test were used to evaluate pleiotropy and heterogeneity. RESULTS Using the inverse-variance weighting method, higher serum MMP-12 levels were found to be associated with an increased risk of VTE (odds ratio, 1.04; 95% confidence interval, 1.01 to 1.07; p=0.001). Moreover, there was a weak association between the levels of certain MMPs and VTE. Sensitivity analyses revealed no significant heterogeneity and pleiotropy in our study, and the Steiger directionality test did not reveal a significant reverse causation association. CONCLUSIONS There is a causal association between MMP-12 levels and VTE, which may have substantial implications for the diagnostic and therapeutic strategies used for VTE.
Abstract
OBJECTIVES Serum matrix metalloproteinase (MMP) levels are associated with cardiovascular diseases. However, the causal associations between serum levels of specific MMPs and venous thromboembolism (VTE) remain unclear. The present study sought to explore the causal relationship between serum MMP levels and VTE by using the Mendelian randomization (MR) method. METHODS In this study 2-sample MR study, the exposure data on serum MMP levels were derived from genome-wide association studies involving 21,758 individuals from 13 cohorts of European descent. The outcome data on VTE, including deep vein thrombosis and pulmonary embolism, were derived from the FinnGen research project. The primary method used was the inverse-variance weighting method. The MR-Egger intercept test and the Cochran Q test were used to evaluate pleiotropy and heterogeneity. RESULTS Using the inverse-variance weighting method, higher serum MMP-12 levels were found to be associated with an increased risk of VTE (odds ratio, 1.04; 95% confidence interval, 1.01 to 1.07; p=0.001). Moreover, there was a weak association between the levels of certain MMPs and VTE. Sensitivity analyses revealed no significant heterogeneity and pleiotropy in our study, and the Steiger directionality test did not reveal a significant reverse causation association. CONCLUSIONS There is a causal association between MMP-12 levels and VTE, which may have substantial implications for the diagnostic and therapeutic strategies used for VTE.
참고문헌 (49)
- Khan F, "Venous thromboembolism", Lancet, 398, pp.64~77 (2021)[DOI]
- Lutsey PL, "Epidemiology and prevention of venous thromboembolism", Nat Rev Cardiol, 20, pp.248~262 (2023)[DOI]
- Duffett L, "Deep venous thrombosis", Ann Intern Med, 175, pp.ITC129~ITC144 (2022)[DOI]
- Guntupalli SR, "Prevention of venous thromboembolism in patients with cancer", BMJ, 381, pp.e072715~ (2023)[DOI]
- de Almeida LG, "Matrix metalloproteinases : from molecular mechanisms to physiology, pathophysiology, and pharmacology", Pharmacol Rev, 74, pp.712~768 (2022)[DOI]
- Mahalanobish S, "Matrix metalloproteinase : an upcoming therapeutic approach for idiopathic pulmonary fibrosis", Pharmacol Res, 152, pp.104591~ (2020)[DOI]
- Li K, "The past, present and future perspectives of matrix metalloproteinase inhibitors", Pharmacol Ther, 207, pp.107465~ (2020)[DOI]
- Chen AY, "Targeting metalloenzymes for therapeutic intervention", Chem Rev, 119, pp.1323~1455 (2019)[DOI]
- Bräuninger H, "Matrix metalloproteinases in coronary artery disease and myocardial infarction", Basic Res Cardiol, 118, pp.18~ (2023)[DOI]
- Grillet B, "Matrix metalloproteinases in arthritis : towards precision medicine", Nat Rev Rheumatol, 19, pp.363~377 (2023)[DOI]
- Piperigkou Z, "Estrogen receptor-mediated targeting of the extracellular matrix network in cancer", Semin Cancer Biol, 62, pp.116~124 (2020)[DOI]
- Li W, "Systemic lupus erythematosus is associated with lower risk of hepatitis B virus infection : a multivariable Mendelian randomization study in East Asian population", J Med Virol, 95, pp.e29226~ (2023)[DOI]
- Emdin CA, "Mendelian randomization", JAMA, 318, pp.1925~1926 (2017)[DOI]
- Davies NM, "Reading Mendelian randomisation studies : a guide, glossary, and checklist for clinicians", BMJ, 362, pp.k601~ (2018)[DOI]
- Lawlor DA, "Commentary : two-sample Mendelian randomization : opportunities and challenges", Int J Epidemiol, 45, pp.908~915 (2016)[DOI]
- Folkersen L, "Genomic and drug target evaluation of 90 cardiovascular proteins in 30, 931 individuals", Nat Metab, 2, pp.1135~1148 (2020)[DOI]
- Tan JS, "Genetically predicted obesity and risk of deep vein thrombosis", Thromb Res, 207, pp.16~24 (2021)[DOI]
- Verbanck M, "Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases", Nat Genet, 50, pp.693~698 (2018)[DOI]
- Bowden J, "Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression", Int J Epidemiol, 47, pp.1264~1278 (2018)[DOI]
- Palmer TM, "Using multiple genetic variants as instrumental variables for modifiable risk factors", Stat Methods Med Res, 21, pp.223~242 (2012)[DOI]
- Chen H, "Protective effects of circulating TIMP3 on coronary artery disease and myocardial infarction : a Mendelian randomization study", J Cardiovasc Dev Dis, 9, pp.277~ (2022)[DOI]
- Huedo-Medina TB, "Assessing heterogeneity in meta-analysis : Q statistic or I2 index?", Psychol Methods, 11, pp.193~206 (2006)[DOI]
- Bowden J, "Mendelian randomization with invalid instruments : effect estimation and bias detection through Egger regression", Int J Epidemiol, 44, pp.512~525 (2015)[DOI]
- Tao T, "Investigating the causal relationship and potential shared diagnostic genes between primary biliary cholangitis and systemic lupus erythematosus using bidirectional Mendelian randomization and transcriptomic analyses", Front Immunol, 15, pp.1270401~ (2024)[DOI]
- Liang X, "Bidirectional two-sample Mendelian randomization analysis reveals a causal effect of interleukin-18 levels on postherpetic neuralgia risk", Front Immunol, 14, pp.1183378~ (2023)[DOI]
- Zhao Z, "Causal relationships between serum matrix metalloproteinases and estrogen receptor-negative breast cancer : a bidirectional Mendelian randomization study", Sci Rep, 13, pp.7849~ (2023)[DOI]
- Lee KJ, "Causal effect of the 25-hydroxyvitamin D concentration on cerebral small vessel disease : a Mendelian randomization study", Stroke, 54, pp.2338~2346 (2023)[DOI]
- Dale CE, "Causal associations of adiposity and body fat distribution with coronary heart disease, stroke subtypes, and type 2 diabetes mellitus : a Mendelian randomization analysis", Circulation, 135, pp.2373~2388 (2017)[DOI]
- van Es N, "Diagnostic management of acute pulmonary embolism : a prediction model based on a patient data meta-analysis", Eur Heart J, 44, pp.3073~3081 (2023)[DOI]
- Tan R, "The pathogenesis of aging-induced left atrial appendage thrombus formation and cardioembolic stroke in mice is influenced by inflammation-derived matrix metalloproteinases", Thromb Res, 226, pp.69~81 (2023)[DOI]
- Yu G, "The expression of matrix metalloproteinases and their tissue inhibitors in the vein wall following superficial venous thrombosis", Phlebology, 37, pp.63~71 (2022)[DOI]
- Kaireviciute D, "Characterisation and validity of inflammatory biomarkers in the prediction of post-operative atrial fibrillation in coronary artery disease patients", Thromb Haemost, 104, pp.122~127 (2010)[DOI]
- Cárcel-Márquez J, "Causal effect of MMP-1(matrix metalloproteinase-1), MMP-8, and MMP-12 levels on ischemic stroke : a Mendelian randomization study", Stroke, 52, pp.e316~e320 (2021)[DOI]
- Jia Y, "Causal associations of serum matrix metalloproteinase-8 level with ischaemic stroke and ischaemic stroke subtypes : a Mendelian randomization study", Eur J Neurol, 28, pp.2543~2551 (2021)[DOI]
- Zou X, "Promising therapeutic targets for ischemic stroke identified from plasma and cerebrospinal fluid proteomes : a multicenter Mendelian randomization study", Int J Surg, 110, pp.766~776 (2024)[DOI]
- Palm F, "Biomarkers of periodontitis and inflammation in ischemic stroke : a case-control study", Innate Immun, 20, pp.511~518 (2014)[DOI]
- Hsieh FI, "Combined effects of MMP-7, MMP-8 and MMP-26 on the risk of ischemic stroke", J Clin Med, 8, pp.2011~ (2019)[DOI]
- Peeters W, "Collagenase matrix metalloproteinase-8 expressed in atherosclerotic carotid plaques is associated with systemic cardiovascular outcome", Eur Heart J, 32, pp.2314~2325 (2011)[DOI]
- Kormi I, "Matrix metalloproteinase-8 and tissue inhibitor of matrix metalloproteinase-1 predict incident cardiovascular disease events and all-cause mortality in a population-based cohort", Eur J Prev Cardiol, 24, pp.1136~1144 (2017)[DOI]
- Tuomainen AM, "Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men", Arterioscler Thromb Vasc Biol, 27, pp.2722~2728 (2007)[DOI]
- Kennedy R, "Recurrent upper extremity arterial thrombosis preceding a diagnosis of COVID-19", Ann Vasc Surg Brief Rep Innov, 3, pp.100148~ (2023)[DOI]
- Kerzeli IK, "Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer", BMC Cancer, 23, pp.605~ (2023)[DOI]
- Zhou X, "Macrophage-derived MMP12 promotes fibrosis through sustained damage to endothelial cells", J Hazard Mater, 461, pp.132733~ (2024)[DOI]
- Stawski L, "MMP-12 deficiency attenuates angiotensin II-induced vascular injury, M2 macrophage accumulation, and skin and heart fibrosis", PLoS One, 9, pp.e109763~ (2014)[DOI]
- Aristorena M, "MMP-12, secreted by pro-inflammatory macrophages, targets endoglin in human macrophages and endothelial cells", Int J Mol Sci, 20, pp.3107~ (2019)[DOI]
- Amor M, "Genetic deletion of MMP12 ameliorates cardiometabolic disease by improving insulin sensitivity, systemic inflammation, and atherosclerotic features in mice", Cardiovasc Diabetol, 22, pp.327~ (2023)[DOI]
- Belaaouaj AA, "Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation", J Biol Chem, 275, pp.27123~27128 (2000)[DOI]
- Challa SR, "The interplay between MMP-12 and t-PA in the brain after ischemic stroke", Neurochem Int, 161, pp.105436~ (2022)[DOI]
- Koolwijk P, "Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12 : implication for angiogenesis in fibrin matrices", Blood, 97, pp.3123~3131 (2001)[DOI]